Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. 2009

Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan, China.

Isoniazid is a widely used drug for the treatment of tuberculosis, but hepatotoxicity is a major concern during treatment. Thiopronin contains an SH-group and is generally considered an antioxidant. The aim of the present study was to investigate the effects of thiopronin during liver injury and DNA damage induced by isoniazid. Rats were injected daily with isoniazid (100 mg/kg, i.p.) for 21 days with or without thiopronin co-administration (60 mg/kg, i.p.) from day 11 to day 21. The influence of thiopronin on isoniazid-induced DNA oxidative damage was analyzed in precision-cut rat liver slices by HPLC-MS/MS. Thiopronin prevented isoniazid-induced hepatotoxicity, indicated by both diagnostic indicators of liver damage (alanine aminotransferase and aspartate aminotransferase) and histopathological analysis. In vivo, thiopronin significantly inhibited isoniazid-induced CYP2E1 activity as assessed by both chlorzoxazone hydroxylase and aniline hydroxylase (p<0.001). Thiopronin concentration-dependently inhibited CYP2E1-dependent aniline hydroxylation, and the Dixon plots suggest that thiopronin is a competitive inhibitor of CYP2E1. Thiopronin markedly attenuated isoniazid-induced inhibition of the detoxification system through cytosolic glutathione S-transferases (GSTs), including mu GST and alpha GST. In precision-cut liver slices, the free radical scavenging activity of thiopronin reduced the generation of DNA adducts induced by isoniazid (p<0.05). Altogether, these results suggest that thiopronin exerts its hepatoprotective activity against isoniazid-induced hepatotoxicity by inhibiting the production of free radicals in addition to its role as a scavenger. Thiopronin may reduce free radical generation via inhibition of hepatic CYP2E1 and increase the removal of free radicals directly or through the induction of cytosolic GSTs.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008297 Male Males
D008625 Tiopronin Sulfhydryl acylated derivative of GLYCINE. Mercaptopropionylglycine,Thiopronine,2-Mercaptopropionylglycine,2-Thiol-propionamido-acetic Acid,2-Thiolpropionamidoacetic Acid,Acadione,Captimer,Meprin,Thiola,Tiopronine,alpha-Mercaptopropionylglycine,2 Mercaptopropionylglycine,2 Thiol propionamido acetic Acid,2 Thiolpropionamidoacetic Acid,Acid, 2-Thiol-propionamido-acetic,Acid, 2-Thiolpropionamidoacetic,alpha Mercaptopropionylglycine
D002753 Chlorzoxazone A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) Paraflex,Parafon,Parafon Forte DSC
D003849 Deoxyguanosine A nucleoside consisting of the base guanine and the sugar deoxyribose.
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
February 2000, Fitoterapia,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
January 2015, Journal of biochemical and molecular toxicology,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
June 2019, Environmental science and pollution research international,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
April 2001, Archives of pharmacal research,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
April 2022, Biotechnic & histochemistry : official publication of the Biological Stain Commission,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
July 2013, The AAPS journal,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
August 2020, Naunyn-Schmiedeberg's archives of pharmacology,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
April 2011, European journal of pharmacology,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
January 2013, PloS one,
Jiang Yue, and Guicheng Dong, and Chunyan He, and Jie Chen, and Yinghui Liu, and Renxiu Peng
October 2011, Molecules (Basel, Switzerland),
Copied contents to your clipboard!